Pharmaceutical - Pharmaceutical, North America, Genito-urinary

Regulatory briefs from GSK/Theravance, Allergan and Mylan


UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX0 have submitted a…

AllerganAnoro ElliptaBotoxEuropeGenericsGenito-urinaryGlaxoSmithKlineMylan LaboratoriesNorth AmericaPharmaceuticalQualaquinRegulationRelvarRespiratory and PulmonaryTheravanceTropical diseases

FDA approves Astellas' Myrbetriq for overactive bladder


The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

FDA advisory panel backs Astellas OAB drug mirabegron


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive…

Genito-urinarymirabegronNorth AmericaPharmaceuticalRegulation

Back to top